Pfizer says it will advance once-daily GLP-1 pill after all

Taking stock of the drug industry, from the lab to the medicine chest

July 11, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Jeenah Moon/Getty Images STAT+ | Pfizer says it will advance once-daily GLP-1 pill after all After a setback with a twice-daily version, Pfizer says its once-daily version of danuglipron is ready to move ahead. By Matthew Herper and Elaine Chen STAT+ | Roche's TIGIT study was a bust. What's the outlook for its next big bet? Plus: A closer look at the outlook for Roche's next big TIGIT bet, as well as some background on TIGIT underdogs iTeos and GSK. By Adam Feuerstein STAT+ | Novo Nordisk's weekly insulin rejected by FDA The company said Wednesday that the FDA made requests related to the manufacturing process and the use of icodec specifically in type 1 diabetes patients. By Elaine Chen Mark Lennihan/AP Opinion: Doctors 'overprescribing' opioids isn't the cause of the overdose epidemic — and it never was The federal government has blamed the overdose epidemic on clinicians overprescribing opioids. That's false — and was never true. By Richard A. "Red" Lawhern

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser